The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment.

 

BUFFALO, NY - November 18, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled, “Mitigating bias in radiology: The promise of topological data analysis and simplicial complexes.”

Bisphenols used in manufacturing products as ‘harmless’ alternatives to BPA pose a health risk, according to a UMH study. Many bisphenols present in everyday items interfere with the body’s hormones. These chemicals are associated with an increased risk of obesity, diabetes, and cancer.

A team of researchers from NIH’s National Library of Medicine and National Cancer Institute developed an AI algorithm that could successfully identify relevant clinical trials for which a person is eligible and provide a summary that clearly explains how that person meets the criteria for study enrollment. The tool can help make it easier for both clinicians and patients to find and connect with the right clinical trial opportunities.

Funded by the BBVA Foundation, the event is taking place from 18 until 20 November at the Casa de Convalescència.

The conference aims to drive new therapeutic strategies to improve cancer treatment.

While substantial progress has been made in sharing data from clinical trials, many top-selling medicines still fall short when it comes to making data publicly accessible, according to new Flinders University research.

Researchers led by Prof. HU Zheng from SIAT, uncovered a polyclonal origin of tumors, challenging the traditional clonal evolution theory. Using a DNA barcoding system in mouse models and genomic analysis of human colorectal samples, they demonstrated that colorectal precancers often arise from multiple distinct cellular lineages, which later transition to monoclonality as tumors progress. These findings, published in Nature, provide critical insights into the early evolution of colorectal cancer and offer new opportunities for preventing malignant transformation.

Researchers at the University of Toronto’s Faculty of Applied Science & Engineering have designed a new microfluidic platform that allows forunprecedented control and manipulation of tumor shapes — a largely unexplored area with great potential to advance cancer research.   

The work, led by Professor Edmond Young, offers new insights into how the shape of tumours can predict cancer cell behaviour and aggressiveness, which opens new pathways for more personalized and targeted cancer care.